Henry Jemil Esber

Primedica Cambridge, Inc. is based in Cambridge, MA. Primedica Cambridge, Inc. provides testing services to the medical industry. The company was founded by Michael Lovell. Primedica Cambridge was acquired by rEVO Biologics, Inc. on July 17, 1995 for $2.40 million.

Mason Laboratories, Inc. develops and produces recombinant proteins for therapeutic and diagnostic uses. The company is based in Worcester, MA and ultimately controlled by the Government of France.

Bio-Quant, Inc. develops natural product components for treatment of cancer and diseases. The company is headquartered in San Diego, CA.

Innovus Pharmaceuticals, Inc. engages in the commercialization, licensing, and development of non-prescription medicine, and consumer care products for health and vitality, and respiratory diseases. Its products focuses in six main categories, including sexual health, pain management, general muscle health, respiratory, sleep, and diabetic care. The company was founded on January 15, 1959 and is headquartered in Englewood, CO.

Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA.

Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA.

BioXyTran, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The company was founded in 2017 and is headquartered in Newton, MA.